117 related articles for article (PubMed ID: 22342674)
1. Breaking through a roadblock in prostate cancer research: an update on human model systems.
Toivanen R; Taylor RA; Pook DW; Ellem SJ; Risbridger GP
J Steroid Biochem Mol Biol; 2012 Sep; 131(3-5):122-31. PubMed ID: 22342674
[TBL] [Abstract][Full Text] [Related]
2. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines.
Gu Y; Li H; Miki J; Kim KH; Furusato B; Sesterhenn IA; Chu WS; McLeod DG; Srivastava S; Ewing CM; Isaacs WB; Rhim JS
Exp Cell Res; 2006 Apr; 312(6):831-43. PubMed ID: 16413016
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
5. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
6. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
Logothetis CJ; Navone NM; Lin SH
Clin Cancer Res; 2008 Mar; 14(6):1599-602. PubMed ID: 18347159
[TBL] [Abstract][Full Text] [Related]
7. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
8. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
9. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer.
Kasper S; Smith JA
J Urol; 2004 Jul; 172(1):12-9. PubMed ID: 15201729
[TBL] [Abstract][Full Text] [Related]
10. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
12. Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer.
Howard EW; Ling MT; Chua CW; Cheung HW; Wang X; Wong YC
Clin Cancer Res; 2007 Mar; 13(6):1847-56. PubMed ID: 17363541
[TBL] [Abstract][Full Text] [Related]
13. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
[TBL] [Abstract][Full Text] [Related]
14. Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin.
Olson KA; Byers HR; Key ME; Fett JW
Clin Cancer Res; 2001 Nov; 7(11):3598-605. PubMed ID: 11705882
[TBL] [Abstract][Full Text] [Related]
15. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.
Wang Q; Tiffen J; Bailey CG; Lehman ML; Ritchie W; Fazli L; Metierre C; Feng YJ; Li E; Gleave M; Buchanan G; Nelson CC; Rasko JE; Holst J
J Natl Cancer Inst; 2013 Oct; 105(19):1463-73. PubMed ID: 24052624
[TBL] [Abstract][Full Text] [Related]
16. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.
Chauchereau A; Al Nakouzi N; Gaudin C; Le Moulec S; Compagno D; Auger N; Bénard J; Opolon P; Rozet F; Validire P; Fromont G; Fizazi K
Exp Cell Res; 2011 Feb; 317(3):262-75. PubMed ID: 20974126
[TBL] [Abstract][Full Text] [Related]
17. Overcoming castration resistance in prostate cancer.
Tsao CK; Small AC; Galsky MD; Oh WK
Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
[TBL] [Abstract][Full Text] [Related]
18. Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
Suckow MA; Rosen ED; Wolter WR; Sailes V; Jeffrey R; Tenniswood M
Cancer Immunol Immunother; 2007 Aug; 56(8):1275-83. PubMed ID: 17242926
[TBL] [Abstract][Full Text] [Related]
19. The human PC346 xenograft and cell line panel: a model system for prostate cancer progression.
Marques RB; van Weerden WM; Erkens-Schulze S; de Ridder CM; Bangma CH; Trapman J; Jenster G
Eur Urol; 2006 Feb; 49(2):245-57. PubMed ID: 16413664
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
